将抗 CD19 CAR T 细胞疗法转化为复发/难治性弥漫性大 B 细胞淋巴瘤的临床实践。
Translating anti-CD19 CAR T-cell therapy into clinical practice for relapsed/refractory diffuse large B-cell lymphoma.
机构信息
Division of Medical Oncology, Department of Medicine, University of Washington, Seattle, WA.
Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA; and.
出版信息
Blood. 2018 Aug 23;132(8):777-781. doi: 10.1182/blood-2018-04-839217. Epub 2018 Jun 18.
Chimeric antigen receptor T cells demonstrate efficacy in B-cell malignancies, leading to US Food and Drug Administration approval of axicabtagene ciloleucel (October 2017) and tisagenlecleucel (May 2018) for large B-cell lymphomas after 2 prior lines of therapy. Durable remissions are seen in 30% to 40% of study-treated patients, but toxicities of cytokine release syndrome and neurotoxicity require administration in specialized centers. This article reviews data of current diffuse large B-cell lymphoma management, focusing on axicabtagene ciloleucel, tisagenlecleucel, and lisocabtagene maraleucel.
嵌合抗原受体 T 细胞在 B 细胞恶性肿瘤中显示出疗效，导致美国食品和药物管理局批准 axicabtagene ciloleucel（2017 年 10 月）和 tisagenlecleucel（2018 年 5 月）用于 2 线治疗后的大 B 细胞淋巴瘤。在接受研究治疗的患者中，30%至 40%的患者出现持久缓解，但细胞因子释放综合征和神经毒性的毒性需要在专门的中心进行管理。本文回顾了当前弥漫性大 B 细胞淋巴瘤管理的数据，重点介绍了 axicabtagene ciloleucel、tisagenlecleucel 和 lisocabtagene maraleucel。
Zotero 插件